Use of Ultra-high Field MRI for In and Ex Vivo Neuroimaging

The relatively low T1 contrast, long T1 (and respectively short T2/T2*) values at higher fields lead to the necessity to adapt sequences commonly used at lower fields. High-resolution studies especially on mice benefit greatly from UHF and for very SNR demanding applications UHF MRI can additionally be combined with an MRI CryoProbe.

In this webinar, Dr. Mathieu D. Santin from ICM, Paris, France, will describe methods and results obtained for in and ex vivo imaging at ultra-high field in the context of neurodegenerative diseases (demyelinating diseases, Alzheimer disease, multiple sclerosis…). For the investigation of such diseases at UHF Santin primarily implements Multi Gradient Echo (MGE) and 3D-segmented Diffusion EPI techniques. Other innovative studies combining ultrasound and MRI to open the blood brain barrier will be discussed as well. Focused Ultrasound (FUS) are used for instance for cortical activations in primates (Transcranial Focused Ultrasound) but also for non-invasively modulating the visual cortex activity of primates by local ultrasound-induced delivery of an inhibitory neurotransmitter (GABA) : transient disruption of the blood brain barrier (BBB) with FUS coupled with ultrasound contrast agents (UCA).

This webinar took place on October 10th 2019

What to Expect

MR methods for high resolution imaging, diffusion weighted imaging, quantitative susceptibility mapping applied to neurodegenerative diseases; use of Focused-ultrasound combined with MRI studies (cortical activations, blood brain barrier opening…).

Key Topics

  • MR methods and results for high resolution imaging
  • Applications for neurodegenerative diseases
  • Combination of ultrasound and MR techniques

Who Should Attend?

People interested in preclinical MRI, ex vivo MRI, neurodegenerative diseases, highly-resolved anatomical and diffusion MRI, Quantitative Susceptibility Mapping, ultrasound-based MRI studies.


Dr. Mathieu D. Santin

Project leader, Neuroimaging platform, CENIR, Brain and Spine Institute (ICM), Paris, France.

After completing his PhD in ultrasound and contrast agents, Mathieu D. Santin performed postdoctorial studies in neuroimaging where he developed new methods based on blood brain barrier opening with ultrasound to monitor amyloid load in mice models. He then joined the Brain and Spine Institute to develop neuroimaging projects. 


Input value is invalid.

Are you already in contact with your Bruker representative regarding any product inquiries?

We constantly want to improve our service for our customers. In answering the following question you help us to serve your needs even better in the future: What best describes your situation?

By ticking this box, I agree to receive, from time to time, emails from Bruker and its affiliates within the Bruker Group on upcoming events, webinars, our products and services, surveys and Bruker's corporate news.
I can unsubscribe at any time, by contacting Bruker or clicking on the opt-out link in the email if available. For more information on the processing of your personal data, please check Bruker’s Privacy Policy. 

By submitting this form I agree my personal data will be used to process my registration to the webinar. I have read and accepted the Bruker Website Privacy Notice ( and I agree to the Terms of Use ( of the Bruker website.

Already registered and lost your invitation link?

Thank you. The invitation link has been resent.